Develops drugs for benign prostatic hyperplasia.
Dec 2023Revenue $0.00/yrExpenses $8.35M/yr
No trend
Figures by year
When will Nymox Pharmaceutical be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2023, revenue was $0.00 and expenses $8.35M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2023 | $0.00 | $8.35M | −$8.35M |
| Dec 2022 | $0.00 | $6.65M | −$6.65M |
| Dec 2021 | $0.00 | $12.5M | −$12.5M |
| Dec 2020 | $5.00K | $11.7M | −$11.7M |
| Dec 2019 | $116K | $13.4M | −$13.3M |
| Dec 2018 | $299K | $10.9M | −$10.6M |
| Dec 2017 | $224K | $13.5M | −$13.2M |
| Dec 2016 | $284K | $13.2M | −$12.9M |
| Dec 2015 | $2.76M | $20.4M | −$17.7M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.